What Valthos does

Valthos is a New York-based, Delaware-incorporated private company building frontier AI systems for biodefense. Its core product, the Valthos Biodefense Platform, rapidly characterizes biological sequences to identify biological threats and then designs and updates medical countermeasures in real time, with the stated objective of closing the asymmetry between the speed at which biology can be weaponized and the speed at which defensive therapeutics can be developed. The platform combines anomaly detection for pathogen identification, generative AI for countermeasure design, and autonomous agents that update medical countermeasures with limited human intervention, positioning the system as a single integrated stack rather than a modular suite of point tools.

The company sells directly to government agencies and life-sciences enterprises through an enterprise field-sales motion, with a stated subscription/recurring revenue model and quote-based pricing that is not publicly disclosed. Its initial customer base comprises two primary segments — government biodefense buyers and life-sciences researchers — and the company has signaled intent to extend the underlying technology toward adaptive, precision therapeutics in commercial life-sciences applications beyond its initial biodefense focus.

Valthos was founded in 2025 by a team drawn from Palantir, DeepMind, the Broad Institute, and the Arc Institute, and closed a $30 million seed round co-led by the OpenAI Startup Fund, Lux Capital, and Founders Fund. The company publicly launched in October 2025 alongside Bloomberg press coverage and is operating with a 1–10 person headcount while actively hiring to scale its AI infrastructure and commercial delivery.

Name

Valthos

Legal name

Valthos, Inc.

Website

https://valthos.com

Company type

Private

Founded year

2025

Operating status

Operating

Headcount range

1–10 employees

Short description

Valthos is a New York-based biodefense company developing frontier AI systems that characterize biological sequences and design real-time medical countermeasures. It serves government agencies and life-sciences researchers, backed by $30 million in seed funding from OpenAI Startup Fund, Lux Capital, and Founders Fund.

Ownership category

akta.pro rank

Product category

Biodefense AI Software

NAICS

Software Publishers (513210), Computer Systems Design and Related Services (54151)

SIC

In Vitro & In Vivo Diagnostic Substances (2835), Services-Computer Programming Services (7371)

akta.pro primary industry

LLMOps & Generative AI Platforms (Prompt/Agent Orchestration, RAG) (HDAEANAD)

akta.pro secondary industries

LLM/GenAI Guardrails & Safety Controls (policy, filtering, routing) (HDAAAKAD), SaMD – Monitoring, Triage & Risk Stratification Software (HLACANAE)

Keywords

• Biodefense AI
• Biological threat detection
• Medical countermeasure design
• Biological sequence analysis
• Pathogen detection

Headquarters

HQ city

New York

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2B

Offering type

Software

Cost components

Personnel, Technology or R&D, Infrastructure, Marketing or Sales, Operations

Revenue model

1. Government Biodefense Solutions: AI-driven systems sold to government agencies for rapid pathogen detection and real-time medical countermeasure updates to enhance biodefense capabilities

Go-to-market motion1 record

Distribution channels1 record

Marketing channels4 records

Core offering

Valthos develops frontier AI systems that rapidly characterize biological sequences and design medical countermeasures in real time. The platform identifies biological threats and updates medicines to match the speed at which biological threats emerge, serving government agencies and life sciences stakeholders.

Product overview

Valthos offers a single unified AI-powered biodefense platform rather than a modular product suite. The core platform integrates biological threat identification and medical countermeasure design into one system, enabling real-time response to biological threats for government and life sciences clients.

Differentiator

Problem solved

Functional benefit

Products and services

• Valthos Biodefense Platform A frontier AI system that rapidly characterizes biological sequences and designs medical countermeasures in real time, intended for government agencies and life sciences organizations for biological threat detection and adaptive therapeutics development.

Named customers2 records

Segments2 records

Ideal customer profiles2 records

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability4 records

Feature3 records

Scale indicators2 records

Recent moves5 records

Expansion highlights5 records

Direct peers

• Isomorphic Labs: Alphabet/DeepMind spinout applying frontier AI to drug discovery. Directly comparable talent lineage (DeepMind co-founder) and core thesis of using frontier AI for biological countermeasure/therapeutic design.
• Insitro: AI/ML-driven drug discovery platform combining machine learning with biological data. Comparable to Valthos in applying frontier ML to life sciences, with similar talent pedigree and platform-oriented thesis.
• Recursion Pharmaceuticals: AI-driven drug discovery platform using high-throughput biology and ML. Shares Valthos's platform-based approach to applying AI/ML across biological sequence characterization and therapeutic development.
• AbCellera Biologics: AI/ML-enabled antibody discovery platform with both pharma and government customers (including pandemic preparedness programs). Comparable business model combining frontier tech with life sciences and government biodefense buyers.
• HelixNano: AI-driven RNA design and biosecurity platform focused on pandemic preparedness and countermeasure development. Directly comparable to Valthos in the AI-biodefense category with overlapping use cases in biological threat response.

Broad incumbents

• Anduril Industries: AI-driven defense technology company selling to government agencies. Comparable go-to-market (direct enterprise sales to US government/defense) and category-defining investor profile relevant to Valthos's government trajectory.
• Palantir Technologies: Data analytics and AI software for government and defense. Multiple Valthos founders come from Palantir, and it represents the established template for selling AI-driven enterprise software to defense/intelligence customers.
• Ginkgo Bioworks: Synthetic biology platform with an explicit biosecurity and biodefense program (Biosecurity by Ginkgo / Concentric). Larger and broader than Valthos, but competes for similar government biosecurity dollars and life sciences customers.
• Booz Allen Hamilton: Major government contractor with a dedicated biodefense and biosecurity practice. Competes for the same government biodefense budgets and represents the established incumbent procurement pathway Valthos must displace or partner with.
• Anthropic: AI safety-focused frontier AI lab. Mission-adjacent to Valthos given its explicit emphasis on biosecurity risks of frontier models; competes for AI safety talent and capital though operating in a different product layer.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks7 records

Key highlights6 records

Customer concentration

• Xx.com/ValthosTech
• LinkedInlinkedin.com/company/valthos

Revenue estimate

Valuation estimate

Number of profiles

Funding overview

Funding rounds1 record

Investors3 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Valthos